Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHugo W. Moser Research Institute at Kennedy Krieger, Inc.
About this trial
This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.
Eligibility criteria
Qualifiers
Age 18 to 75 years old.
Have received a clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)/long COVID syndrome using the criteria specified by Thaweethai, et al., 2023 (JAMA). This symptom checklist provides a score based on the number and severity of symptoms. An individual with a score >12 is classified as having PASC.
Currently experiencing Fatigue/Brain Fog as assessed with the Post-COVID symptom checklist and the PedsQL questionnaire.
Disqualifiers
Neurological disorders including, but not limited to, stroke, head injury, epilepsy, seizures, brain tumors, brain surgery, Parkinson's Disease, or any other neuromuscular disease (self-report).
Diagnosed history of severe psychiatric diseases such as depression and schizophrenia (self-report).
Congestive heart failure.
Peripheral artery disease with claudication.
Trial design
Treatments tested in this trial
- Physical Fatigue
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov